- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.07. | Fierce Pharma Asia-More AstraZeneca China deals; Kailera, Hengrui's oral GLP-1 data; Scrutiny of Chinese trials | 5 | FiercePharma | ||
| 08.07. | Kailera's big obesity reveal puts pressure on shares | - | pharmaphorum | ||
| 08.07. | Why KL Residents Were Excluded From Governance Reforms Decisions, KLRA Asks | 3 | BusinessToday | ||
| KAILERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.07. | Why Is Kailera Therapeutics Stock Falling Tuesday? | 1 | Benzinga.com | ||
| 07.07. | Kailera says obesity pill succeeds in late-stage trial in China | 2 | BioPharma Dive | ||
| 07.07. | Kailera falls after late-stage trial data for oral GLP-1 candidate | 1 | Seeking Alpha | ||
| 07.07. | Kailera's oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials | 1 | FierceBiotech | ||
| 29.06. | Kailera Therapeutics, Inc.: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer | 386 | GlobeNewswire (Europe) | WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment... ► Artikel lesen | |
| 06.06. | Kailera Therapeutics, Inc.: Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026 | 5 | GlobeNewswire (USA) | ||
| 27.05. | Kailera's three-pronged obesity shot shows promise in early trial | 2 | BioPharma Dive | ||
| 26.05. | Kailera Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 26.05. | Kailera Therapeutics, Inc. - 8-K, Current Report | 10 | SEC Filings | ||
| 26.05. | Kailera Therapeutics, Inc.: Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates | 846 | GlobeNewswire (Europe) | Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injection... ► Artikel lesen | |
| 26.05. | Kailera Therapeutics, Inc. reports Q1 results | 2 | Seeking Alpha | ||
| 16.05. | Is Kailera Therapeutics a Buy After Its Sizzling IPO? | 3 | The Motley Fool | ||
| 12.05. | TD Cowen initiates Kailera stock with buy on weight loss drug potential | 7 | Investing.com | ||
| 12.05. | William Blair initiates Kailera stock with Outperform rating | 1 | Investing.com | ||
| 12.05. | William Blair startet Coverage für Kailera mit "Outperform" | 7 | Investing.com Deutsch | ||
| 12.05. | Jefferies stuft Kailera mit "Buy" ein: Adipositas-Pipeline als Kurstreiber | 11 | Investing.com Deutsch | ||
| 12.05. | JPMorgan startet Kailera-Aktie mit "Overweight" - Adipositas-Pipeline im Fokus | 7 | Investing.com Deutsch |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,464 | +0,93 % | Übernahmekandidaten! Steyr Motors nach 20 %-Sprung! RE Royalties spannend! Und was macht Evotec? | Um 20 % ist die Aktie von Steyr Motors in der vergangenen Woche kurzzeitig explodiert. Grund waren Übernahmespekulationen durch einen Drohnen- und Robotikspezialisten aus den USA. Die Gespräche wurden... ► Artikel lesen | |
| QIAGEN | 36,460 | +0,89 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| STRYKER | 292,50 | -0,24 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders... ► Artikel lesen | |
| NOVONESIS | 57,00 | -0,18 % | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| TEMPUS AI | 45,180 | +0,30 % | BTIG cuts Tempus AI stock price target to $70 on model update | ||
| VIDAC PHARMA | 0,441 | -1,56 % | PTA-DD: Vidac Pharma Holding PLC: Mitteilung über Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR | DJ PTA-DD: Vidac Pharma Holding PLC: Mitteilung über Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR
Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR
Vidac Pharma Holding... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,84 | 0,00 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,390 | 0,00 % | If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| RELAY THERAPEUTICS | 19,770 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 361,08 | +0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DYNE THERAPEUTICS | 26,250 | 0,00 % | PetAg expands Tractor Supply distribution of supplements, life-stage nutrition: The company's Dyne Soft Chews and Esbilac ... | ||
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,040 | -0,11 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Executive Chair Transition | BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,290 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
KAILERA THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,05 % bei einem Aktienkurs von 18,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAILERA THERAPEUTICS INC finden Sie auf Wallstreet Online.